Marker Therapeutics provided an update on the Phase 1 APOLLO study showcasing encouraging overall response rates in relapsed B cell lymphoma.
66% of Non-Hodgkin Lymphoma (NHL) patients achieved objective response rates, with 50% showing complete response (CR).
The study demonstrated a favorable safety profile with no dose limiting toxicities or immune-effector cell associated neurotoxicity syndrome observed in the dose escalation cohort.
Objective Response Rates
66% of NHL patients achieved objective response rates with 50% showing CR.
Safety Profile
No dose limiting toxicities or neurotoxicity syndrome observed in the dose escalation cohort.
Dose Expansion Phase
Investigating MT-601 at pre-specified maximum dose in Diffuse Large B Cell Lymphoma patients.
Live Webcast
A live webcast will be held to discuss the study results at 8:30 a.m. ET.
- MT-601 showed promise in heavily pre-treated lymphoma patients who had relapsed after previous therapies, including CAR-T cells and bispecific antibodies.
- The data indicated durable responses with continued responses lasting up to 24 months in some patients, addressing a critical unmet need in lymphoma treatment.
Marker Therapeutics' Phase 1 APOLLO study results highlight the potential of MT-601 in addressing the unmet needs of heavily pre-treated lymphoma patients, paving the way for further advancements in immunotherapy for hematological malignancies.